Understanding Antibody Responses to COVID-19 Vaccines
Author Information
Author(s): Bangaru Sandhya, Jackson Abigail M., Copps Jeffrey, Fernández-Quintero Monica L., Torres Jonathan L., Richey Sara T., Nogal Bartek, Sewall Leigh M., Torrents de la Peña Alba, Rehman Asma, Guebre-Xabier Mimi, Girard Bethany, Das Rituparna, Corbett-Helaire Kizzmekia S., Seder Robert A., Graham Barney S., Edwards Darin K., Patel Nita, Smith Gale, Ward Andrew B.
Primary Institution: Cold Spring Harbor Laboratory
Hypothesis
How do the mRNA-1273 and NVX-CoV2373 vaccines induce antibody responses?
Conclusion
Both vaccines generate diverse antibody responses, but the NTD supersite is particularly vulnerable to mutations.
Supporting Evidence
- The study examined the antigenicity of mRNA-1273 and NVX-CoV2373 vaccines.
- Both vaccines induce diverse polyclonal antibody responses.
- The NTD supersite was identified as an immunodominant epitope.
- High-resolution studies revealed unique angles of antibody engagement.
- NTD supersite antibodies are more susceptible to variant mutations.
Takeaway
The study looked at how two COVID-19 vaccines help our bodies fight the virus by making antibodies, and found that one part of the virus is more likely to change and make those antibodies less effective.
Methodology
Electron microscopy-based polyclonal epitope mapping of serum from immunized non-human primates and clinical trial donors.
Participant Demographics
Non-human primates and clinical trial donors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website